Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hematopoietic stem cell disorder characterized by a global deficiency of glycosylphospatidyl inositol-anchored proteins (GPI-APs) on the membrane of all cell types derived from the affected stem cell. 1 The corresponding clinical phenotype results from the deficiency of GPI-AP on individual cells, and includes a triad of intravascular hemolytic anemia, propensity for thrombosis and bone marrow failure inherently linked to the properties of the affected stem cell. Although the PNH phenotype is non-malignant, outgrowth of GPI-AP (-) clones is mediated by a selective advantage in the context of a permissive condition, such as autoimmune-mediated bone marrow suppression as seen in aplastic anemia.
2 The GPI-AP (-) phenotype results from mutations of the PIG-A gene, located at Xp22.2, which participates in GPI synthesis. 3 Because the gene is X-linked, a single frame-shift or missense inactivating mutation results in loss of GPI-AP expression on the cell surface and because of the X-chromosome inactivation, the frequency of PNH is similar in men and women.
New cytogenetic technologies, such as single-nucleotide polymorphism array-based karyotyping, show superb resolution allowing for detection of submicroscopic chromosomal defects not seen on metaphase spreads. 4 We have systematically applied this technology to identify clonal aberrations in patients with various forms of bone marrow failure.
5 During this molecular screen, a microdeletion of Xp22.2, encompassing the PIG-A locus, was found in three patients with PNH. We have shown that in addition to PIG-A mutations, PNH results from clonal deletion of chromosomal material, likely leading to the same selective clonal advantage as hypomorphic mutation of the PIG-A gene.
The initial observation was made through analysis of a 51-year-old male whose initial presentation of PNH included a thrombotic event (patient #1). The workup of thrombophilia included testing for PNH using flow cytometry; the patient showed diagnostic GPI-AP (-) granulocytes and mild intravascular hemolysis (Figure 1a, left) . On the basis of these findings a diagnosis of a classic PNH was made. Additional testing showed the presence of a JAK2V617F mutation. Laboratory workup included sequencing of PIG-A mRNA in sorted GPI-deficient and normal granulocytes. However, PNH granulocytes yielded no PIG-A complementary DNA amplification product and quantitative PCR demonstrated a lack of PIG-A amplicons from the GPI-AP (-) granulocytes using the normal cell population as the calibrator (Figure 1a, center) . This peculiar finding led to the review of single-nucleotide polymorphism array karyograms from sorted PNH and normal granulocytes; a microdeletion of the PIG-A locus at Xp22.2 was identified in PNH cells while normal cells had an intact X chromosome, confirming the somatic nature of the microdeletion (Figure 1a, right) . The microdeletion spanned 555 kb from bases 15 189 545 to 15 744 107 and included the genes ASB9, ASB and PIR, as well as PIG-A.
We subsequently studied a cohort of patients positive for a significant PNH clone (420%; N ¼ 31) (Table 1) using singlenucleotide polymorphism array karyotyping. We identified two additional patients with deletions of Xp22.2. Analogous to the index patient, in the second case (patient # 21), clinical workup was consistent with a diagnosis of PNH, however, JAK2 testing revealed the presence of a V617F mutation. Because nearly all granulocytes were GPI-AP (-) (Figure 1b, left) , corresponding normal granulocytes could not be isolated in sufficient numbers for analysis and we instead separated unaffected lymphocytes. qPCR for PIG-A mRNA expression in the GPI-AP (-) cells showed a complete lack of expression of PIG-A in PNH granulocytes (Figure 1b, center) . The deletion on Xp22.2 spanned 506 kb from bases 15235264 to 15758377 and included PIG-A, as well the neighboring genes ASB9, ASB1, PIR and BMX (Figure 1b, right) . The third patient (patient #28) was a 27-year-old female with a long-standing diagnosis of hemolytic PNH and an almost complete deficiency of normal granulocytes (Figure 1c, left) . In this patient a somatic deletion of the PIG-A locus included nucleotide sequence 15055660 to 15671999, for a total of 616 kb (Figure 1c, right) . Although phenotypically normal cells showed PIG-A expression, virtually no PIG-A amplification product could be obtained in PNH cells (Figure 1c, center) . As the deletion in this patient was hemizygous, the most likely mechanism leading to loss of PIG-A expression is deletion of the allele on the un-inactivated X chromosome. Sequencing of all exons of the remaining PIG-A allele did not reveal any mutations.
Here, we report for the first time patients with apparent PNH and no PIG-A mutations. Instead, the GPI-AP (-) hematopoietic clone results from a microdeletion of the X chromosome encompassing the PIG-A locus. Our observation suggests that in addition to mutations, PNH can be due to a distinct molecular mechanism, namely a chromosomal aberration involving the PIG-A locus. Although three instances of small intragenic deletions, including two p4 kb and one with undefined breakpoints limited to the PIG-A gene, have been reported previously, 6,7 our study describes the first cases of PNH due to a true genomic aberration of Xq22 (B500 kb), spanning a number of genes, including PIG-A. There are important implications of this finding with regard to the biology of the disease, as well as its relationship to clonal malignant disorders of hematopoiesis.
The frequency of PNH in men and women is similar. Because of the localization of PIG-A to the X chromosome, the mechanism of action of the deletion leading to loss of PIG-A expression differs Letters to the Editor between men (with one X chromosome) and women (with two X chromosomes). In men, hemizygous deletion of PIG-A would always lead to PNH. However, in women the deletion must occur on the active X chromosome to lead to loss of PIG-A transcription and thereby GPI-AP (-) clonal expansion. Therefore, female PNH patients who show deficient PIG-A expression in the PNH clone may be not only due to nonsense mutations but also due a chromosomal loss involving PIG-A locus on Xp22.2.
Although JAK2 mutations were present in two cases of PNH with Xp22.2 deletion (patients # 1 and 21), JAK2 was not mutated in the third patient (patient # 28). The association between JAK2 and PNH has been investigated in a larger independent study (manuscript in preparation).
Consequently, our findings suggest that the clonal advantage of hematopoietic stem cells with a PNH phenotype may be achieved by various mechanisms. Loss of chromosomal material rather than point mutation in patients with a PNH phenotype may point toward chromosomal instability implicated in the evolution of unbalanced chromosomal aberrations in myelodysplastic syndrome. Deletion of the X chromosome occurs relatively frequently in females with myelodysplastic syndrome and has been also observed in various leukemic cell lines. Thus, one could conclude that while in PNH, PIG-A mutations occur after X chromosome Figure 1 Characterization of GPI-AP-deficient clone in patients with PNH and an X-chromosome deletion. (a) The presence of a clonal granulocyte population deficient for GPI-AP in patient #1 was detected by flow cytometry using an antibody to CD11b and FLAER. A CD11b þ FLAER-population, corresponding to a PNH clone, was found to comprise 98.8% of the granulocytes (left). PIG-A mRNA expression was determined using quantitative PCR. No expression was detected in the PNH clone when the normal granulocytes were used as a calibrator (center). Single-nucleotide polymorphism array (SNP-A) analysis of the X chromosome in this patient identified a microdeletion of Xq22.2 in the PNH granulocytes (blue box), but not the WT granulocytes, which contained PIG-A (right). The purity of the cell fractions analyzed is illustrated in the scatterplots to the right of the SNP-A karyograms. (b) Analysis of the PNH clone in patient #21 (left). PIG-A mRNA expression analysis showed no expression in the PNH clone (center). In this patient, normal lymphocytes were used as the calibrator because sufficient numbers of normal granulocytes could not be isolated. SNP-A analysis of the X chromosome showed a deletion in the PNH population but not in normal granulocytes (right). (c) Flow cytometric analysis of the PNH clone in patient #28 (left). In this patient, the GPI-AP-deficient granulocyte population comprised 95%. PIG-A mRNA expression showed reduced expression (0.007) in PNH granulocytes when normal granulocytes were used as the calibrator (center). A deletion of Xp22.2 was identified by SNP-A-based karyotyping (right).
Letters to the Editor inactivation and therefore PNH shows a similar incidence in women, deletion of the X chromosome in clonal myeloid malignancies may rather involve the inactivated or partially inactivated homolog, as the function of PIG-A appears intact in these cases (not shown). Nevertheless, interstitial deletions of various chromosomal regions are common in myelodysplastic syndrome, but the clonal advantage in cases of Xp22.2 is not only due to hemizygosity of a tumor suppressor gene but also due to deficiency of the PIG-A gene. In this setting, loss of PIG-A or a combination of genes within the 0.5 Mb commonly deleted region leads to a phenotype capable of avoiding immune surveillance, but is not inherently malignant. As such, it has been hypothesized that instead of autonomous growth, extrinsic factors may provide a fertile environment for clonal evolution in PNH. 8 In sum, we have identified a molecularly distinct subtype of PNH due to deletion of X-chromosome material.
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This work was supported in part by RO1HL-082983, U54 RR019391 K24 HL-077522 and by grant from AA&MDS International Foundation and Robert Duggan Charitable Fund (JPM). IDH1 and IDH2 mutations are rare in pediatric myeloid malignancies Leukemia (2011) 25, 382-384; doi:10.1038 /leu.2010 published online 14 January 2011 Recently, recurrent somatic missense mutations in NADP þ -dependent isocitrate dehydrogenase gene (IDH1) at codon R132, as well as IDH2 at codon R172, have been identified in low-grade gliomas/secondary glioblastoma by high-throughput sequencing.
1 Subsequent studies also revealed that acquired somatic mutations in IDH1 frequently occurred in adult hematological malignancies, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
2,3 More recently, Paschka et al. 4 reported that not only IDH1 but also IDH2 mutations occurred relatively frequently in adult AML, and that these mutations were associated with older age, poor prognosis, cytogenetically normal AML (CN-AML) and the genotype of mutated NPM1 without FLT3-internal tandem duplication (ITD). Exon 4 of both IDH1 and IDH2, which was previously identified as a hot spot for mutations in these genes, encodes three arginine residues (R100, R109 and R132 in IDH1 and R140, R149, and R172 in IDH2) that are important for protein activities.
5 Tumor-derived IDH1 and IDH2 mutations impair the affinity of enzymes for substrates, and dominantly inhibit wild-type IDH1 and IDH2 activities through the formation of catalytically inactive heterodimers.
5 Ho et al. 6 previously reported that IDH1 mutations are not detected in pediatric AML; however, little is known about the incidence and prognostic values of IDH1 and IDH2 mutations in pediatric myeloid malignancies. Here, we analyzed mutations that involve the activation sites of IDH1 and IDH2 (exon 4 and exon 7 in both IDH1 and IDH2) using genomic DNApolymerase chain reaction amplification/sequencing in a total of 199 samples of pediatric myeloid malignancies, including 17 AML-derived cell lines, 115 primary cases of AML, 28 primary cases of MDS, 15 primary cases of juvenile myelomonocytic leukemia (JMML), 6 chronic myeloid leukemia (CML)-derived cell lines and 18 primary cases of CML. Moreover, to assess whether IDH1 and IDH2 mutations overlap with known gene abnormalities, such as FLT3, c-KIT and NPM1 mutations, mutational analyses of FLT3, c-KIT and NPM1 were also performed in AML samples. This study was approved by the ethics committee of the University of Tokyo (Approval Number 3043).
The common IDH2 R140Q mutation was detected in a single AML case, whereas no IDH1 mutation including G123E, as well as no other IDH2 mutations, such as R172K, were detected in our study (Figure 1) . The IDH2 R140Q mutation detected in the AML case was a heterozygous substitution. No IDH1 and IDH2 mutations were detected in the JMML, MDS or CML samples examined. As the additional activation sites of both IDH1 and IDH2 are located in exon 7 of these genes, direct sequencing of exon 7 of IDH1 and IDH2 was also performed, but no mutations were detected in our series. Six AML samples including one cell line had c-KIT mutations (D816V, N822K and D419fs), and 12 AML samples had FLT3-ITD. The NPM1 mutation was detected in 2 of 132 AML samples. The AML case harboring the IDH2 mutation, case 39, showed no abnormalities of NPM1, c-KIT and FLT3. Case 39 was a 12-year-old boy diagnosed as AML-M2 according to the French-American-British cooperative group classification system. Bone marrow blasts obtained at initial diagnosis showed t(8;21)(q22;q22). After complete remission was achieved by the ACMP (adriamycin, cytarabine, 6-mercaptopurine, prednisolone) two-step induction therapy, the patient underwent consolidation therapy every 5 weeks, but hematological relapse occurred 11 months after the initial diagnosis. He was treated with low-dose cytarabine, but died 5 months after relapse with progressive disease. To assess the genetic mechanisms involved in the pathogenesis of the disease of this case, we further performed genome-wide copy number analysis of bone marrow blasts obtained at initial diagnosis of this case, using single-nucleotide polymorphism (SNP)-genotype microarrays (Affymetrix GeneChip Mapping 250 K StyI arrays, 
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